Vitamin K deficiency in critical ill patients; a prospective observational study.
J Crit Care
; 49: 105-109, 2019 02.
Article
em En
| MEDLINE
| ID: mdl-30415179
ABSTRACT
BACKGROUND:
Vitamin K is a cofactor for proteins involved in cardiovascular health, bone metabolism and cancer. Measuring uncarboxylated prothrombin, also termed as "protein induced by vitamin K absence or antagonism for factor II (PIVKA-II)", has been used to assess vitamin K status. High levels may indicate vitamin K deficiency. The aim of this study was to measure PIVKA-II and prothrombin time (PT-INR) in intensive care (ICU) patients and correlate vitamin K status with mortality.METHODS:
Ninety-five patients admitted to the ICU had blood samples taken near admission and every third day. In addition to PIVKA-II and PT-INR, critical-care severity scores were computed.RESULTS:
The median baseline PIVKA-II was 4.97⯵g/L compared to the upper reference of 2.0⯵g/L. PIVKA-II further increased at days 3 and 6, (median 7.88⯵g/L, pâ¯=â¯.047 and median 8.14⯵g/L, pâ¯=â¯.011) predominantly in cardiac arrest patients (median 21.4⯵g/L, day 3).CONCLUSION:
Intensive care patients have increased PIVKA-II levels at admission, which increases during the ICU stay, especially in cardiac arrest patients. There were no correlations between PIVKA-II and PT-INR, SOFA score or mortality. Further studies are needed to determine why PIVKA-II increases and whether high PIVKA-II levels in ICU patients affect long-term mortality or morbidity.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Precursores de Proteínas
/
Deficiência de Vitamina K
/
Protrombina
/
Biomarcadores
/
Estado Terminal
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article